Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.5 USD | -0.15% | -3.79% | -7.14% |
17/05 | HC Wainwright Adjusts Kala Pharmaceuticals Price Target to $18 From $21, Maintains Buy Rating | MT |
02/04 | HC Wainwright Trims KALA BIO's Price Target to $21 From $22, Keeps Buy Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.14% | 1.83Cr | |
+38.69% | 72TCr | |
+34.28% | 59TCr | |
-4.49% | 37TCr | |
+20.24% | 33TCr | |
+2.12% | 28TCr | |
+17.02% | 24TCr | |
+9.31% | 21TCr | |
-5.07% | 21TCr | |
-0.35% | 17TCr |
- Stock Market
- Equities
- KALA Stock
- News KALA BIO, Inc.
- Transcript : Kala Pharmaceuticals, Inc., Q3 2021 Earnings Call, Nov 15, 2021